Candice McCoy

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

Lia Gore, Mace L. Rothenberg, Cindy L. O’Bryant et al. · Clinical Cancer Research · 2008 · 173 citations · Full text

Medicine, Oncology, Pharmacology +12

12-<i>O</i>-Tetradecanoylphorbol-13-Acetate Activation of the <i>MDR1</i> promoter Is Mediated by EGR1

Candice McCoy, Dirk E. Smith, Marilyn M. Cornwell · Molecular and Cellular Biology · 1995 · 92 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +8

A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer

Eric J. Small, Raymond S. Lance, Thomas A. Gardner et al. · Clinical Cancer Research · 2015 · 84 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours

Edwina N. Scott, Anne Thomas, L Rhoda Molife et al. · Cancer Chemotherapy and Pharmacology · 2009 · 34 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +11

The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter.

Candice McCoy, Sara B. McGee, Marilyn M. Cornwell · PubMed · 1999 · 30 citations

Medicine, Cancer Biology, Oncology +15